98%
921
2 minutes
20
Background: Leiomyosarcoma of the inferior vena cava (IVC) is a rare tumor arising from the smooth muscle of vessel walls. Surgery is the only potential curative treatment. Given its rarity, optimal surgical, and oncologic management is not well described. We review our institutional series of primary leiomyosarcomas treated with resection and IVC reconstruction over the last decade.
Methods: Retrospective chart review of all patients who underwent surgical resection of primary leiomyosarcoma of the IVC from November 2009 to March 2020 at a single tertiary care center was performed.
Results: Among the eight patients treated, the majority were female (87.5%) with a median age of 52 years (range, 44-63). Tumor was located in the infrarenal IVC in five patients (62.5%). IVC was reconstructed using a ring-enforced PTFE graft in six patients (75%). All but one patient had an intermediate (grade 2) or high grade (grade 3) tumor, and all resections achieved grossly negative margins. The 1- and 3-year disease-free survival was 85.7% and 64.3%, respectively. There were no disease-specific deaths during a median follow-up of 36 months (interquartile range, 10-51 months).
Conclusions: With a well-coordinated multidisciplinary approach, primary leiomyosarcoma of the IVC can be safely resected with good long-term survival.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1002/jso.26163 | DOI Listing |
JMIR Res Protoc
September 2025
Department of Medical Oncology, Early Phase Unit, Georges-François Leclerc Centre, Dijon, France.
Background: Sarcomas are rare cancer with a heterogeneous group of tumors. They affect both genders across all age groups and present significant heterogeneity, with more than 70 histological subtypes. Despite tailored treatments, the high metastatic potential of sarcomas remains a major factor in poor patient survival, as metastasis is often the leading cause of death.
View Article and Find Full Text PDFRadiat Oncol
September 2025
Department of Breast Sarcoma and Endocrine Tumors, Karolinska University Hospital, Stockholm, Sweden.
Background: Stereotactic Body Radiotherapy (SBRT) has been proven to be a safe and effective alternative to surgery in patients with metastatic primary sarcoma. However, data describing tumor response in relation to the given radiotherapy dose is lacking. Therefore, this study aims at analyzing efficacy and dose-response relationship in a retrospective cohort.
View Article and Find Full Text PDFOncoscience
September 2025
Division of Pediatric Hematology and Oncology, Kasturba Medical College, Manipal Academy of Higher Education, Manipal, Karnataka, India.
Background: Trophoblastic differentiation or beta-human chorionic gonadotropin (β-hCG) secretion in endometrial carcinoma has been associated with poorly differentiated and aggressive tumors; however, the evidence is largely inconclusive. The review aimed to explore the prognostic role of trophoblastic differentiation and β-hCG in non-trophoblastic, primary uterine corpus cancers.
Methodology: A comprehensive electronic search across databases was conducted for all cases of cancers of the uterine corpus that were either associated with elevated levels of β-hCG or showed evidence of trophoblastic differentiation upon microscopy or both.
Purpose: PTEN loss contributes to aberrant signaling of the phosphatidylinositol 3-kinase (PI3K)/protein kinase B/mammalian target of rapamycin pathway and may confer sensitivity to therapies targeting the PI3K pathway. The PIK3CB inhibitor GSK2636771 demonstrated efficacy in tumors with mutations and may similarly show efficacy in patients with PTEN loss.
Methods: Two nonrandomized, open-label phase II subprotocols within the context of the NCI-MATCH trial targeted PTEN tumor alterations in patients with advanced relapsed/refractory solid tumors, lymphoma, or myeloma: mutation/deletion (arm N) or loss of PTEN protein expression (arm P).
Mol Imaging Biol
August 2025
Harvard Medical School, Boston, MA, USA.
Purpose: Sarcomas, malignancies of mesenchymal origin, present significant diagnostic and therapeutic challenges due to their heterogeneity and low incidence. This review aims to examine the evolving role of fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) in the management of soft tissue and musculoskeletal sarcomas. Specifically, it seeks to evaluate 18F-FDG PET/CT's utility in detecting metastatic lesions, differentiating benign from malignant tumors, and assessing treatment responses.
View Article and Find Full Text PDF